Metsera
Pfizer Finalizes $7.3B Metsera Buy for Next-Gen Obesity Therapy with Monthly Dosing
fizer has entered into a definitive agreement to acquire Metsera for up to $7.3B, gaining MET-097i, a next-gen GLP-1 therapy with ultra-long acting, potentially monthly dosing, strong Phase 2a efficacy, and promising tolerability.